TachyarrhythmiaNCT04863664
Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)
A study testing Defibrillation (RV Implant) and Defibrillation (LBBAP Implant) in people with Tachyarrhythmia, run by Medtronic Cardiac Rhythm and Heart Failure at 55 sites in 20 countries.
Trial summary
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead. The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next… Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Tachyarrhythmia
- What is being tested?
- Defibrillation (RV Implant) and Defibrillation (LBBAP Implant)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 998 participants
- Where
- 55 sitesin 20 countries
- Study dates
- 21 Jun 2021to 6 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
LEADR Inclusion Criteria:
- Subject meets current clinical practice guidelines for implantation of ICD or CRT-D and will undergo one of the following:
- de novo Medtronic CRT-D system implant
- de novo Medtronic ICD system implant (single or dual chamber)
- Subject has, per local law and requirements, the minimum age for autonomously signing an ICF (minimum age of 18 years)
- Subject is willing to undergo implant defibrillation testing if requested.
- Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up.
LEADR Exclusion Criteria:
- Subject is unwilling or unable to personally provide Informed Consent.
- Subject has contraindications for standard RV transvenous lead placement (e.g., mechanical right heart valve).
- Subject is contraindicated for ≤1 mg dexamethasone acetate.
- Subject has a life expectancy of less than 12 months
- For subject undergoing defibrillation testing the following medical conditions exclude them:
- Pre-existing or suspected pneumothorax during implant
- Current intracardiac left atrial or left ventricular (LV) thrombus
- Severe aortic stenosis
- Severe proximal three-vessel or left main coronary artery disease without revascularization
- Unstable angina
- Ejection Fraction less than 25%
- Recent stroke or transient ischemic attack (within the last 6 months)
- Known inadequate external defibrillation
- Any other known medical condition not listed that precludes their participation in the opinion of the investigator
- Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager.
- Subject with any exclusion criteria as required by local law (e.g., age or other).
- Pregnant women or breastfeeding women, or women of childbearing potential and who are not on a reliable form of birth regulation method or abstinence
- Subject with an existing pacemaker (including transcatheter pacing system), ICD, or CRT device or leads
- Subject with any evidence of active infection or undergoing treatment for an infection
- Recent (or planned) cardiac surgery or stenting less than 1 month before implant
- End stage renal disease
- Subjects with NYHA IV classification
- Subjects with a transplanted heart
- Subjects with previously extracted leads
- Subjects with Left Ventricular Assist Device
LEADR LBBAP Inclusion Criteria:
- Subject meets current local clinical practice guidelines for implantation of ICD (single or dual chamber) or CRT-D system and will undergo one of the following:
- De novo Medtronic ICD system implant (single or dual chamber) or b) De novo Medtronic CRT-D system implant and is intended to also undergo LV lead implant (for patients indicated for CRT-D according to locally approved indications/indications)
- Subject is 12 years of age or older and also is greater than 30 kg in weight at time of enrollment, has cardiac anatomy conducive to RV coil placement, and is allowed to participate in study per local law and requirements. Subjects from 12 years of age until adult also have a separate indication for pacing or CRT or are anticipated to develop one.
- Subject provides written authorization and/or consent per institution and geographical requirements.
- Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up
- Subject is willing to undergo implant defibrillation testing if requested
LEADR LBBAP Exclusion Criteria:
- Subject has contraindication for screw-in active fixation transvenous lead placement (e.g., mechanical right heart valve)
- Subject is contraindicated for ≤1 mg dexamethasone acetate
- Subject has a life expectancy of less than 12 months
- For subject undergoing defibrillation testing the following medical conditions exclude them:
- Pre-existing or suspected pneumothorax
- Current intracardiac left atrial or LV thrombus
- Severe aortic stenosis
- Severe proximal three-vessel or left main coronary artery disease without revascularization
- Unstable angina
- Recent stroke or transient ischemic attack (within the last 6 months)
- Known inadequate external defibrillation
- Any other known medical condition not listed that precludes their participation in the opinion of the investigator
- Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager
- Subject is pregnant or breastfeeding, or subject is of childbearing potential and not on a reliable form of birth regulation method or abstinence
- Subject with an existing pacemaker (including transvenous and transcatheter pacing system), ICD (transvenous) or CRT-D (transvenous) device or leads
- Subject with previous subcutaneous ICD (S-ICD), extravascular ICD (EV ICD) or Implantable Cardiac Monitor explanted within 30 days before implant
- Subject with any evidence of active bacterial infection or undergoing treatment for a bacterial infection within the last 30 days
- Recent (or planned) cardiovascular intervention within 30 days before or after implant, such as cardiac surgery, cardiac ablation, Percutaneous Coronary Intervention (PCI), or temporary cardiac pacing for >12 hours
- Subjects with end stage renal disease
- Subjects with NYHA IV classification
- Subjects with a transplanted heart or on the waiting list for a heart transplant
- Subjects with previously extracted leads
- Subjects with Left Ventricular Assist Device
- Subjects that are vulnerable adults
Trial locations and contacts
55 sites in 20 countries.
55 sites in 20 countries
United States23 sites
LEADR: Presbyterian Heart Group
Albuquerque, New Mexico, 87108
LEADR: Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18103
LEADR: Texas Cardiac Arrhythmia Research Foundation
Austin, Texas, 78705
LEADR & LEADR LBBAP: South Shore University Hospital/Northwell Health
Bay Shore, New York, 11030
LEADR & LEADR LBBAP: University of Virginia Medical Center
Charlottesville, Virginia, 22903
LEADR: TriHealth Hatton Research Institute
Cincinnati, Ohio, 45202
LEADR LBBAP: The Christ Hospital
Cincinnati, Ohio, 45219
LEADR: Cleveland Clinic
Cleveland, Ohio, 44195
LEADR LBBAP: The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210
LEADR: Texas Health Fort Worth Hospital
Fort Worth, Texas, 76104
LEADR: Hartford Hospital
Hartford, Connecticut, 06106
LEADR: Heart Center Research
Huntsville, Alabama, 35801
LEADR: Saint Luke's Mid America Heart Institute
Kansas City, Missouri, 64111
LEADR LBBAP: Aurora St. Luke's Hospital
Milwaukee, Wisconsin, 53215
LEADR & LEADR LBBAP: Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, 55407
LEADR& LEADR LBBAP: Vanderbilt University medical Center
Nashville, Tennessee, 37232
LEADR: Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
LEADR & LEADR LBBAP: Virginia Commonwealth University Health System
Richmond, Virginia, 23298
LEADR: Washington University School of Medicine
St Louis, Missouri, 63110
LEADR: University of South Florida
Tampa, Florida, 33606
LEADR LBBAP: Torrance Memorial Medical Center
Torrance, California, 90505
LEADR: Lourdes Cardiology Services
Voorhees Township, New Jersey, 08034
LEADR LBBAP: Geisinger Wyoming Valley Medical Center
Wilkes-Barre, Pennsylvania, 18711
Australia4 sites
LEADR: Ashford Hospital
Ashford, South Australia, 8032
LEADR & LEADR LBBAP: The Prince Charles Hospital
Chermside, Queensland, 4032
LEADR &LEADR LBBAP: Canberra Hospital
Garran, 2605
LEADR & LEADR LBBAP: Royal Adelaide
Norwood, South Australia, 5000
Canada3 sites
LEADR: University of Calgary
Calgary, Alberta, T2N 4N1
LEADR: Southlake Regional Health Centre
Newmarket, Ontario, L3Y8C3
LEADR & LEADR LBBAP: Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Québec, Quebec, G1V 4G5
France3 sites
LEADR: Centre Hospitalier Universitaire de Grenoble - Site Nord
La Tronche, 38700
LEADR LBBAP: OC Santé - Clinique du Millénaire
Montpellier, 34960
LEADR: CHU Hôpitaux de Rouen - Hôpital Charles Nicolle
Rouen, 76031
Japan3 sites
LEADR & LEADR LBBAP: Kokura Memorial Hospital
Kitakyushu, Fukuoka, 802-8555
LEADR: Tokyo Women's Medical University Hospital
Shinjuku-Ku, Tokyo, 162-8666
LEADR & LEADR LBBAP: National Cerebral and Cardiovascular Center
Suita, Osaka, 564-8565
Spain3 sites
LEADR LBBAP: Hospital Universitario Virgen de las Nieves
Granada, Granada, 18014
LEADR: Hospital Universitari Bellvitge
L'Hospitalet de Llobregat
LEADR: Hospital Universitario y Politécnico La Fe
Valencia, 46026
China2 sites
LEADR & LEADR LBBAP: West China Hospital of Sichuan University
Chengdu
LEADR: Shanxi Cardiovascular Hospital
Taiyuan, Shanxi, 030000
Hong Kong2 sites
LEADR & LEADR LBBAP: Queen Mary Hospital
Hong Kong
LEADR: Princess Margaret Hospital
Lai Chi Kok, 999077
Belgium1 site
LEADR LBBAP: Universitair Ziekenhuis Antwerpen
Edegem, Antwerp, 2650
Germany1 site
LEADR: Klinikum Bielefeld Kardiologie
Bielefeld, Bielefeld, 33604
Italy1 site
LEADR: Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
Bergamo, 24127
Malaysia1 site
LEADR & LEADR LBBAP: Institut Jantung Negara - National Heart Institute
Kuala Lumpur, 50400
Netherlands1 site
LEADR LBBAP: Maastricht Universitair Medisch Centrum
Maastricht, Limburg
Portugal1 site
LEADR: Centro Hospitalar de Lisboa Ocidental, E.P.E. Hospital de Santa Cruz Cardiology
Carnaxide, 2790-134
United Kingdom1 site
LEADR & LEADR LBBAP: Imperial College Healthcare NHS Trust - Hammersmith Hospital
London, W12 0HS
About this study
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.
The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
Read the detailed description
The LEADR and LEADR LBBAP studies will enroll subjects who are indicated to receive an implantable single or dual chamber ICD, or CRT-D, and who meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive an investigational Next Generation ICD Lead. Subjects in the LEADR study will be followed for at least 18 months following Next Generation ICD Lead implantation in a septal (non-LBBAP) or apical implant location. Enrollment in the LEADR study has been completed (675 subjects enrolled). Subjects in the LEADR LBBAP study will be followed for at least 3 months (ICD-indicated subjects) or 6 months (CRT-indicated subjects) following Next Generation ICD Lead implantation in an LBBAP implant location. Enrollment in the LEADR LBBAP study has been completed (323 subjects enrolled).
- Conditions
- Tachyarrhythmia
- Being tested
- Defibrillation (RV Implant), Defibrillation (LBBAP Implant)
- Medical subject headings
- Tachycardia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Defibrillation (RV Implant)Device
Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
Defibrillation (LBBAP Implant)Device
Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
| Study group | Role | What they receive |
|---|---|---|
| Intervention/Treatment (LEADR) | Experimental | Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing Receives: Device: Defibrillation (RV Implant) |
| Intervention/Treatment (LEADR LBBAP) | Experimental | Patients will be implanted with a Next Generation ICD Lead in the LBBAP location and undergo required electrical testing Receives: Device: Defibrillation (LBBAP Implant) |
What is being measured
The primary outcome is the main question the study is designed to answer.
LEADR: Estimate the rate of major Lead complication-free rate at 6 months
Subjects free of Next Generation ICD lead-related complication at 6 months post-implant.
Measured: Implant to 6 Months
LEADR: Percentage of subjects successfully defibrillated at implant with the Next Generation ICD lead
Defibrillation testing will be completed in a subset of subjects at implant.
Measured: Day 1
LEADR LBBAP: Percentage of subjects successfully defibrillated at implant with the Next Generation ICD lead
Defibrillation testing will be completed with the Next Generation ICD Lead in the LBBAP location in a subset of subjects at implant.
Measured: Day 1
LEADR LBBAP: The lead-related major complication rate at 3-months
Subjects free of Next Generation ICD lead-related complication at 3 months post-implant.
Measured: Implant to 3 Months
Secondary outcomes (1)
LEADR: Estimate the fracture-free rate of the Next Generation ICD lead
Subjects will be assessed at certain time points for Next Generation ICD lead fracture related to the Next Generation ICD lead.
Measured: up to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Apr 2021
- Study start21 Jun 2021
- Primary completion3 Sep 2025
- Study completion6 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for TachyarrhythmiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 998 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- George Crossley, MD, Principal investigator, Vanderbilt University (LEADR)Pugazhendhi Vijayaraman, MD, Principal investigator, Geisinger Medical Center (LEADR LBBAP)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04863664
- Sponsor's protocol ID
- MDT19004 / MDT22048
- Status last verified
- Apr 2025
- First submitted
- 21 Apr 2021
- Last updated
- 9 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Crossley GH 3rd, Mason PK, Hansky B, De Filippo P, Shah MJ, Philippon F, Sholevar D, Richardson TD, West MB, Dinerman J, Dawson J, Himes A, Severseike L, Thompson AE, Sanders P. High predicted durability for the novel small-diameter OmniaSecure defibrillation lead. Heart Rhythm. 2025 Feb;22(2):302-310. doi: 10.1016/j.hrthm.2024.09.005. Epub 2024 Sep 26.
PubMed 39341436
Study at a glance
From the registry record, last updated by the sponsor on 9 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)
- ClinicalTrials.gov ID
- NCT04863664
- Acronym / sponsor ID
- MDT19004 / MDT22048
- Conditions
- Tachyarrhythmia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 998 participants (actual)
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart FailureIndustry (pharma, biotech, devices)
- Study start
- 21 Jun 2021 (actual)
- Primary completion
- 3 Sep 2025 (actual)
- Study completion
- 6 Nov 2025 (actual)
- First posted
- 28 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.
The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
Detailed description
The LEADR and LEADR LBBAP studies will enroll subjects who are indicated to receive an implantable single or dual chamber ICD, or CRT-D, and who meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive an investigational Next Generation ICD Lead. Subjects in the LEADR study will be followed for at least 18 months following Next Generation ICD Lead implantation in a septal (non-LBBAP) or apical implant location. Enrollment in the LEADR study has been completed (675 subjects enrolled). Subjects in the LEADR LBBAP study will be followed for at least 3 months (ICD-indicated subjects) or 6 months (CRT-indicated subjects) following Next Generation ICD Lead implantation in an LBBAP implant location. Enrollment in the LEADR LBBAP study has been completed (323 subjects enrolled).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention/Treatment (LEADR) | Experimental | Device: Defibrillation (RV Implant)Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing |
| Intervention/Treatment (LEADR LBBAP) | Experimental | Device: Defibrillation (LBBAP Implant)Patients will be implanted with a Next Generation ICD Lead in the LBBAP location and undergo required electrical testing |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Defibrillation (RV Implant)Required electrical testing for pacing, sensing, impedance and defibrillation will be completed | Device | Intervention/Treatment (LEADR) |
| Defibrillation (LBBAP Implant)Required electrical testing for pacing, sensing, impedance and defibrillation will be completed | Device | Intervention/Treatment (LEADR LBBAP) |
Primary outcome
LEADR: Estimate the rate of major Lead complication-free rate at 6 months
Time frame: Implant to 6 Months
Subjects free of Next Generation ICD lead-related complication at 6 months post-implant.
LEADR: Percentage of subjects successfully defibrillated at implant with the Next Generation ICD lead
Time frame: Day 1
Defibrillation testing will be completed in a subset of subjects at implant.
LEADR LBBAP: Percentage of subjects successfully defibrillated at implant with the Next Generation ICD lead
Time frame: Day 1
Defibrillation testing will be completed with the Next Generation ICD Lead in the LBBAP location in a subset of subjects at implant.
LEADR LBBAP: The lead-related major complication rate at 3-months
Time frame: Implant to 3 Months
Subjects free of Next Generation ICD lead-related complication at 3 months post-implant.
1 secondary outcome
LEADR: Estimate the fracture-free rate of the Next Generation ICD lead
Time frame: up to 24 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Dec 2025.
- Derived from this study: PubMed 39341436Crossley GH 3rd, Mason PK, Hansky B, De Filippo P, Shah MJ, Philippon F, Sholevar D, Richardson TD, West MB, Dinerman J, Dawson J, Himes A, Severseike L, Thompson AE, Sanders P. High predicted durability for the novel small-diameter OmniaSecure defibrillation lead. Heart Rhythm. 2025 Feb;22(2):302-310. doi: 10.1016/j.hrthm.2024.09.005. Epub 2024 Sep 26.
- Individual participant dataSharing planned: No
Related trials for Tachyarrhythmia
Recruiting
SPIKE FLOW Endocardial Lead Safety and Performance Study
Acute Myocardial Infarction (AMI), Asystole
Recruiting
Optimal Settings for Anti Tachycardia Pacing (ATP) on ICD
Heart Disease, Implantable Cardioverter Defibrillator (ICD)
RecruitingPhase 4
MEdical Treatment in Idiopathic Ventricular Fibrillation Patients
Idiopathic Ventricular Fibrillation, Cardiac Arrest, Out-Of-Hospital
RecruitingPhase 1
Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial
Ventricular Tachycardia
Enrolling by invitationObservational study
Lead Evaluation for Defibrillation and Reliability Post Approval Study
Tachyarrhythmia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
George Crossley, MD principal investigator
Vanderbilt University (LEADR)
Pugazhendhi Vijayaraman, MD principal investigator
Geisinger Medical Center (LEADR LBBAP)
55 sites in 20 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Defibrillation (RV Implant) and Defibrillation (LBBAP Implant) in people with Tachyarrhythmia, run by Medtronic Cardiac Rhythm and Heart Failure at 55 sites in 20 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 55 sites in United States, Australia, Canada, France, Japan and 15 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
LEADR: Estimate the rate of major Lead complication-free rate at 6 months (time frame: Implant to 6 Months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04863664, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2025.